- Home
- BUD vs AMGN Comparison
BUD vs AMGN Comparison
Compare BUD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- AMGN
- Stock Information
- Founded
- BUD 1366
- AMGN 1980
- Country
- BUD Belgium
- AMGN United States
- Employees
- BUD N/A
- AMGN N/A
- Industry
- BUD Beverages (Production/Distribution)
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BUD Consumer Staples
- AMGN Health Care
- Exchange
- BUD Nasdaq
- AMGN Nasdaq
- Market Cap
- BUD 136.1B
- AMGN 155.9B
- IPO Year
- BUD N/A
- AMGN N/A
- Fundamental
- Price
- BUD $68.91
- AMGN $298.24
- Analyst Decision
- BUD Strong Buy
- AMGN Hold
- Analyst Count
- BUD 4
- AMGN 20
- Target Price
- BUD $72.00
- AMGN $322.30
- AVG Volume (30 Days)
- BUD 2.5M
- AMGN 2.8M
- Earning Date
- BUD 07-31-2025
- AMGN 08-05-2025
- Dividend Yield
- BUD 1.23%
- AMGN 3.19%
- EPS Growth
- BUD 45.11
- AMGN 56.16
- EPS
- BUD 3.38
- AMGN 10.94
- Revenue
- BUD $58,849,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- BUD $1.98
- AMGN $7.73
- Revenue Next Year
- BUD $4.52
- AMGN $1.68
- P/E Ratio
- BUD $20.37
- AMGN $27.25
- Revenue Growth
- BUD N/A
- AMGN 15.56
- 52 Week Low
- BUD $45.94
- AMGN $253.30
- 52 Week High
- BUD $72.13
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- BUD 45.87
- AMGN 61.97
- Support Level
- BUD $68.70
- AMGN $275.70
- Resistance Level
- BUD $69.70
- AMGN $286.17
- Average True Range (ATR)
- BUD 0.73
- AMGN 8.20
- MACD
- BUD -0.36
- AMGN 0.97
- Stochastic Oscillator
- BUD 22.60
- AMGN 96.05
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.